Jasper Therapeutics, Inc.
JSPR
$1.65
$0.074.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -27.55% | 4.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.89% | 24.19% | |||
| Operating Income | 35.89% | -24.19% | |||
| Income Before Tax | 29.89% | -25.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.89% | -25.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.89% | -25.81% | |||
| EBIT | 35.89% | -24.19% | |||
| EBITDA | 36.12% | -24.60% | |||
| EPS Basic | 35.38% | -23.25% | |||
| Normalized Basic EPS | 41.61% | -23.25% | |||
| EPS Diluted | 35.38% | -23.25% | |||
| Normalized Diluted EPS | 41.61% | -23.25% | |||
| Average Basic Shares Outstanding | 8.49% | 2.08% | |||
| Average Diluted Shares Outstanding | 8.49% | 2.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||